Last updated July 17, 2026
Key finding
At 26 weeks, 46.4% of the tofogliflozin group achieved a weight loss of 3% or more, significantly higher than 14.4% in the conventional treatment group (p < 0.001).
This study evaluated the effects of tofogliflozin on patients with type 2 diabetes and obesity, finding significant improvements in weight loss and metabolic parameters.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of tofogliflozin on patients with type 2 diabetes and obesity, finding significant improvements in weight loss and metabolic parameters.
The findings highlight tofogliflozin's potential as an effective treatment option for managing obesity and metabolic issues in patients with type 2 diabetes. This could lead to improved patient outcomes and reduced healthcare costs associated with diabetes-related complications.
The study was a post-hoc analysis, which may limit the robustness of the findings. The sample size and demographic characteristics may affect the generalizability of the results. Long-term effects beyond 104 weeks were not assessed.
Published in
Publication details and source links for this paper.
Naoto K, Tomoya M, Takafumi M, Yasunori S, Hirotaka W, Iichiro S. Effects of Tofogliflozin on Health Issues in Patients with Type 2 Diabetes and Obesity: A Post-hoc Analysis of the UTOPIA Trial. Diabetology international. 2025;16(4):756-769. doi:10.1007/s13340-025-00845-7
At 26 weeks, 46.4% of the tofogliflozin group achieved weight loss of ≥3%, compared to 14.4% in the conventional group (p < 0.001).
At 104 weeks, 62.0% of the tofogliflozin group achieved weight loss of ≥3%, versus 29.3% in the conventional group (p < 0.001).
The tofogliflozin group showed greater improvements in glycated hemoglobin (HbA1c) and fasting plasma glucose.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to SGLT2 inhibitors and Change in arterial stiffness progression, Change in liver indices, Change in urinary albumin levels, and 7 more.
This study contributes evidence to
Primary intervention
SGLT2 inhibitors
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
10
Evidence pairs
876
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
SGLT2 inhibitors → Change in arterial stiffness progression
SGLT2 inhibitors → Change in arterial stiffness progression
SGLT2 inhibitors → Change in liver indices
SGLT2 inhibitors → Change in liver indices
SGLT2 inhibitors → Change in urinary albumin levels
SGLT2 inhibitors → Change in urinary albumin levels
SGLT2 inhibitors → Fasting Plasma Glucose (FPG)
SGLT2 inhibitors → Fasting Plasma Glucose (FPG)
SGLT2 inhibitors → Percentage of patients achieving weight loss of ≥3% at 26 weeks
SGLT2 inhibitors → Percentage of patients achieving weight loss of ≥3% at 26 weeks
SGLT2 inhibitors → Systolic blood pressure
SGLT2 inhibitors → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Change in arterial stiffness progression, SGLT2 Inhibitors and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Change in arterial stiffness progression
Measures Change in arterial stiffness progression as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
